Crossject présente ses résultats financiers et les faits marquants de ses activités pour le premier semestre 2024
23 sept. 2024 12h00 HE
|
CROSSJECT
Position de trésorerie : 5,95 millions d'euros, contre 2,3 millions d’euros au 31 décembre 2023 Investissements stables en R&D et consolidation des revenus d'exploitation de BARDALa société est...
Crossject reports financial results and business highlights for the first six months of 2024
23 sept. 2024 12h00 HE
|
CROSSJECT
Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file...
Crossject organisera un webcast le 6 février à 17h30 pour faire le point sur sa stratégie commerciale
01 févr. 2024 12h15 HE
|
CROSSJECT
Dijon, France, 1 février 2024 – 18 : 15 CET - Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe des auto-injecteurs sans aiguille dédiés aux...
Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
01 févr. 2024 12h15 HE
|
CROSSJECT
Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a...
Vagus Nerve Stimulator Market is Poised to Thrive at CAGR of 10.1% During 2022-2031 | TMR Study
17 avr. 2023 16h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, April 18, 2023 (GLOBE NEWSWIRE) -- The global vagus nerve stimulator market size was worth USD 444.7 Mn in 2021 and is anticipated to exceed value of USD 1.1 Bn...
Stopping Epilepsy Before It Starts? CURE Researcher Identifies a Possible Biomarker
06 févr. 2018 09h50 HE
|
About Citizens United for Research in Epilepsy (CURE)
Chicago, Feb. 06, 2018 (GLOBE NEWSWIRE) -- New research, funded by Citizens United for Research in Epilepsy (CURE), has discovered a ‘smoking gun’ biomarker that could result in treatments that stop...